169 related articles for article (PubMed ID: 16389172)
21. Economic evaluation for pharmaceuticals in Germany.
Jönsson B
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
[No Abstract] [Full Text] [Related]
22. Reimbursement for chemotherapy drugs used in office practice.
Bailes JS
Oncology (Williston Park); 1991 Oct; 5(10):27. PubMed ID: 1838268
[No Abstract] [Full Text] [Related]
23. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
Hoomans T; van der Roer N; Severens JL; Delwel GO
Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
[TBL] [Abstract][Full Text] [Related]
24. Approvals in 2016: cost-benefit challenges of new anticancer agents.
Savage P
Nat Rev Clin Oncol; 2017 Feb; 14(3):133-134. PubMed ID: 28218257
[No Abstract] [Full Text] [Related]
25. Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value.
Serritella AV; Strohbehn GW; Goldstein DA; Lichter AS; Ratain MJ
Clin Pharmacol Ther; 2020 Sep; 108(3):487-493. PubMed ID: 32298471
[TBL] [Abstract][Full Text] [Related]
26. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
Garrison LP
Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218
[No Abstract] [Full Text] [Related]
27. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
Zaric GS; O'brien BJ
Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
[TBL] [Abstract][Full Text] [Related]
28. Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs.
Cohen J; Malins A; Shahpurwala Z
Health Aff (Millwood); 2013 Apr; 32(4):762-70. PubMed ID: 23569057
[TBL] [Abstract][Full Text] [Related]
29. Early Returns From the Era of Precision Medicine.
Cutler DM
JAMA; 2020 Jan; 323(2):109-110. PubMed ID: 31935015
[No Abstract] [Full Text] [Related]
30. Loading doses for costly cancer biologicals: sound pharmacology or unnecessary extravagance?
Epstein RJ; Cheung BM
Eur J Cancer; 2008 Jul; 44(11):1488-92. PubMed ID: 18194858
[TBL] [Abstract][Full Text] [Related]
31. Can treatment costs be tamed?
Malakoff D
Science; 2011 Mar; 331(6024):1545-7. PubMed ID: 21436438
[No Abstract] [Full Text] [Related]
32. No rational theory for drug pricing.
Cox MC; Figg WD; Thurman PW
J Clin Oncol; 2004 Mar; 22(5):962-3. PubMed ID: 14990657
[No Abstract] [Full Text] [Related]
33. The economic crisis and cancer chemotherapy: the role of the oncologist.
Rescigno P; Imbevaro S; Jirillo A
Tumori; 2012; 98(4):532-3. PubMed ID: 23052172
[No Abstract] [Full Text] [Related]
34. [Pharmacoeconomic aspects of breast cancer management].
Kolbin AS; Zagorodnikova KA
Vopr Onkol; 2011; 57(5):604-8. PubMed ID: 22238930
[No Abstract] [Full Text] [Related]
35. Differences in reimbursement listing of anticancer therapies in China: an observational study.
Guan X; Zhang Y; Wushouer H; Shi L; Ross-Degnan D; Wagner AK
BMJ Open; 2020 Jan; 10(1):e031203. PubMed ID: 31911513
[TBL] [Abstract][Full Text] [Related]
36. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
37. [Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital].
Baudouin A; Fargier E; Cerruti A; Dubromel A; Vantard N; Ranchon F; Schwiertz V; Salles G; Souquet PJ; Thomas L; Bérard F; Nancey S; Freyer G; Trillet-Lenoir V; Rioufol C
Bull Cancer; 2017 Jun; 104(6):538-551. PubMed ID: 28237353
[TBL] [Abstract][Full Text] [Related]
38. FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.
Bach PB; Giralt SA; Saltz LB
JAMA; 2017 Nov; 318(19):1861-1862. PubMed ID: 28975266
[No Abstract] [Full Text] [Related]
39. Coalition Priorité Cancer and the pharmaceutical industry in Quebec: conflicts of interest in the reimbursement of expensive cancer drugs?
Hughes D; Williams-Jones B
Healthc Policy; 2013 Aug; 9(1):52-64. PubMed ID: 23968674
[TBL] [Abstract][Full Text] [Related]
40. Oncology drugs enter the US market faster than in Europe but cost more.
Mitka M
JAMA; 2012 Aug; 308(6):555. PubMed ID: 22871850
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
